| Name | Title | Contact Details |
|---|
Clinical Match™ is a physician-founded community of clinical investigators, patients, volunteers, and providers working towards the advancement of medicine.
HI Bio is a clinical stage biotechnology company focused on the development of targeted therapies for patients with immune mediated diseases (IMDs).
Improving the lives of people with severe illness or injury takes more than skill and compassion - it takes innovation. A national leader in long term acute care, LifeCare was built on the belief that early and aggressive intervention, coupled with a personalized treatment plan that encompasses body, mind and soul, can maximize a patient`s potential for recovery. Our multi-disciplinary treatment teams are directed by highly-trained, committed physicians and include healthcare professionals involved in all aspects of a patient`s care: nurses, respiratory therapists, physical medicine specialists, radiologists, pharmacists, dietitians and case managers. Our philosophy has impacted the lives of thousands of LifeCare patients, resulting in improved outcomes, shorter hospital stays and more cost-effective treatment. Based in Plano, Texas, the LifeCare Family of Hospitals includes both freestanding and "hospital-in-hospital" acute care hospitals designed to treat medically complex patients who require acute care hospital services for an extended period of time. Currently, our network includes 24 locations in 9 states.
ARTMS Inc. is the global leader in the development of novel technologies and products for enabling the cyclotron production of the world’s most-used diagnostic imaging isotopes.
TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.